文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

急性应激性(Takotsubo)心肌病的心肌与全身炎症

Myocardial and Systemic Inflammation in Acute Stress-Induced (Takotsubo) Cardiomyopathy.
PubMed 文献 · Circulation · 2019-01-01

该多中心前瞻性研究纳入55例Takotsubo心肌病患者与51例匹配对照,用USPIO增强心脏磁共振检测心肌巨噬细胞炎症,并分析单核细胞亚群与血清细胞因子。结果显示患者心肌USPIO增强、IL-6及CXCL1升高、经典单核细胞增多而中间型和非经典型减少;5个月后心肌USPIO增强消失,但IL-6升高和中间型单核细胞减少持续存在。

要点

  • Takotsubo心肌病急性期存在心肌巨噬细胞炎症浸润和全身促炎细胞因子升高。
  • 急性期单核细胞亚群分布改变:经典CD14++CD16-增多,中间型和非经典型减少。
  • 5个月后心肌USPIO增强消失,但IL-6升高和中间型单核细胞减少持续存在。

核心结论

  • Takotsubo心肌病以心肌巨噬细胞炎症浸润、单核细胞亚群分布改变和全身促炎细胞因子升高为特征。
  • 部分炎症改变持续至少5个月,提示低度慢性炎症状态。

研究设计与样本

  • 多中心前瞻性研究,纳入55例Takotsubo心肌病患者和51例年龄、性别及合并症匹配的对照。
  • 患者在急性期和5个月随访时接受多参数心脏磁共振(含USPIO增强检测心肌炎症巨噬细胞)及血单核细胞亚群和血清细胞因子检测。
  • 对照仅在单时间点接受检查。

主要发现

  • 患者USPIO增强(以pre-USPIO与post-USPIO的T2*差值表示)在气球样变节段为14.3±0.6 ms,对照为10.5±0.9 ms(P<0.001)。
  • 患者在非气球样变节段的USPIO增强为12.9±0.6 ms,对照为10.5±0.9 ms(P=0.02)。
  • 患者血清IL-6为23.1±4.5 pg/mL,对照为6.5±5.8 pg/mL(P<0.001);CXCL1为1903±168 pg/mL,对照为1272±177 pg/mL(P=0.01)。
  • 患者经典CD14++CD16-单核细胞为90±0.5%,对照为87±0.9%(P=0.01);中间型CD14++CD16+为5.4±0.3%,对照为6.9±0.6%(P=0.01);非经典CD14+CD16++为2.7±0.3%,对照为4.2±0.5%(P=0.006)。
  • 5个月时心肌USPIO增强不再可检测到,但血清IL-6仍持续升高(P=0.009),中间型CD14++CD16+单核细胞仍降低(5.6±0.4% vs 6.9±0.6%,P=0.01)。

临床怎么用

  • 提示炎症机制参与Takotsubo心肌病,可关注IL-6等炎症指标及单核细胞亚群变化。
  • 心肌USPIO增强在5个月时消失,但全身炎症指标可持续异常,随访中不应仅依赖心脏影像。

局限性

  • 对照仅单时间点检查,无法对比对照的纵向变化。
  • 样本量有限(55例患者和51例对照),结论需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acute stress-induced (takotsubo) cardiomyopathy can result in a heart failure phenotype with a prognosis comparable with that of myocardial infarction. In this study, we hypothesized that inflammation is central to the pathophysiology and natural history of takotsubo cardiomyopathy. METHODS: In a multicenter study, we prospectively recruited 55 patients with takotsubo cardiomyopathy and 51 age-, sex-, and comorbidity-matched control subjects. During the index event and at the 5-month follow-up, patients with takotsubo cardiomyopathy underwent multiparametric cardiac magnetic resonance imaging, including ultrasmall superparamagnetic particles of iron oxide (USPIO) enhancement for detection of inflammatory macrophages in the myocardium. Blood monocyte subpopulations and serum cytokines were assessed as measures of systemic inflammation. Matched control subjects underwent investigation at a single time point. RESULTS: Subjects were predominantly middle-aged (64±14 years) women (90%). Compared with control subjects, patients with takotsubo cardiomyopathy had greater USPIO enhancement (expressed as the difference between pre-USPIO and post-USPIO T2*) in both ballooning (14.3±0.6 milliseconds versus 10.5±0.9 milliseconds; P<0.001) and nonballooning (12.9±0.6 milliseconds versus 10.5±0.9 milliseconds; P=0.02) left ventricular myocardial segments. Serum interleukin-6 (23.1±4.5 pg/mL versus 6.5±5.8 pg/mL; P<0.001) and chemokine (C-X-C motif) ligand 1 (1903±168 pg/mL versus 1272±177 pg/mL; P=0.01) concentrations and classic CD14++CD16- monocytes (90±0.5% versus 87±0.9%; P=0.01) were also increased whereas intermediate CD14++CD16+ (5.4±0.3% versus 6.9±0.6%; P=0.01) and nonclassic CD14+CD16++ (2.7±0.3% versus 4.2±0.5%; P=0.006) monocytes were reduced in patients with takotsubo cardiomyopathy. At 5 months, USPIO enhancement was no longer detectable in the left ventricular myocardium, although persistent elevations in serum interleukin-6 concentrations ( P=0.009) and reductions in intermediate CD14++CD16+ monocytes (5.6±0.4% versus 6.9±0.6%; P=0.01) remained. CONCLUSIONS: We demonstrate for the first time that takotsubo cardiomyopathy is characterized by a myocardial macrophage inflammatory infiltrate, changes in the distribution of monocyte subsets, and an increase in systemic proinflammatory cytokines. Many of these changes persisted for at least 5 months, suggesting a low-grade chronic inflammatory state. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT02897739.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Scally C, Abbas H, Ahearn T, et al. Myocardial and Systemic Inflammation in Acute Stress-Induced (Takotsubo) Cardiomyopathy. Circulation. 2019. PMID: 30586731. doi:10.1161/CIRCULATIONAHA.118.037975

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。